Gold Fields Limited vs Kymera Therapeutics Inc. Common Stock — how do they compare? Gold Fields Limited trades at $36.68 (market cap $32.51B), while Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.87B). The key difference: Gold Fields Limited is far larger — about 3.7× Kymera Therapeutics Inc. Common Stock's market cap, and Gold Fields Limited pays a 5.92% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gold Fields Limited for 50 Days and Kymera Therapeutics Inc. Common Stock for 0 Days on average.
| GFI | KYMR | |
|---|---|---|
Market Cap | $32.51B | $8.87B |
Volume | 3,490,155 | 779,107 |
Sector | Basic Materials | Health |
52-Week High | $61.52 | $127.31 |
52-Week Low | $31.25 | $55.80 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | $33.11B | $8.26B |
Dividend Yield | 5.92% | — |
Signals from Pluang's Aura AI — not financial advice
Gold Fields (GFI) trades at $35.55, down 3.29% amid market reaction to its rejected $27 billion bid for Northern Star. Despite recent earnings misses, the company shows strong fundamentals with a low P/E of 7.4, robust net income margin of 38.66%, and record 2025 revenue of $8.75 billion. Technical indicators are bearish, with the stock near key support at $36. Analyst consensus remains positive with a $52.75 price target, though sentiment is cautious due to acquisition uncertainty.
The outlook for GFI is mixed; its undervalued metrics and high profitability support upside potential, but near-term volatility from the failed acquisition and bearish technicals pose risks. Investors should weigh the company's strong cash flow generation and growth prospects against execution risks and gold price sensitivity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →